Risk for Life-Threatening Cardiac Events in Patients With Genotype-Confirmed Long-QT Syndrome and Normal-Range Corrected QT Intervals  by Goldenberg, Ilan et al.
F
M
R
o
G
C
c
L
V
C
P
Journal of the American College of Cardiology Vol. 57, No. 1, 2011
© 2011 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00
PRisk for Life-Threatening Cardiac Events
in Patients With Genotype-Confirmed Long-QT
Syndrome and Normal-Range Corrected QT Intervals
Ilan Goldenberg, MD,* Samuel Horr, MA,* Arthur J. Moss, MD,* Coeli M. Lopes, PHD,†
Alon Barsheshet, MD,* Scott McNitt, MS,* Wojciech Zareba, MD, PHD,* Mark L. Andrews, BBA,*
Jennifer L. Robinson, MS,* Emanuela H. Locati, MD,§ Michael J. Ackerman, MD, PHD,¶
Jesaia Benhorin, MD, Elizabeth S. Kaufman, MD,# Carlo Napolitano, MD,**††
Pyotr G. Platonov, MD, PHD,§§ Silvia G. Priori, MD, PHD,**†† Ming Qi, MD,‡
Peter J. Schwartz, MD,‡‡ Wataru Shimizu, MD, PHD, Jeffrey A. Towbin, MD,¶¶
G. Michael Vincent, MD,*** Arthur A. M. Wilde, MD, PHD,## Li Zhang, MD***
Rochester and New York, New York; Milan and Pavia, Italy; Tel Aviv, Israel; Rochester, Minnesota; Cleveland, Ohio;
Lund, Sweden; Suita, Japan; Houston, Texas; Amsterdam, the Netherlands; and Salt Lake City, Utah
Objectives This study was designed to assess the clinical course and to identify risk factors for life-threatening events in
patients with long-QT syndrome (LQTS) with normal corrected QT (QTc) intervals.
Background Current data regarding the outcome of patients with concealed LQTS are limited.
Methods Clinical and genetic risk factors for aborted cardiac arrest (ACA) or sudden cardiac death (SCD) from birth
through age 40 years were examined in 3,386 genotyped subjects from 7 multinational LQTS registries, catego-
rized as LQTS with normal-range QTc (440 ms [n  469]), LQTS with prolonged QTc interval (440 ms
[n  1,392]), and unaffected family members (genotyped negative with 440 ms [n  1,525]).
Results The cumulative probability of ACA or SCD in patients with LQTS with normal-range QTc intervals (4%) was signifi-
cantly lower than in those with prolonged QTc intervals (15%) (p  0.001) but higher than in unaffected family
members (0.4%) (p  0.001). Risk factors ACA or SCD in patients with normal-range QTc intervals included mu-
tation characteristics (transmembrane-missense vs. nontransmembrane or nonmissense mutations: hazard ra-
tio: 6.32; p  0.006) and the LQTS genotypes (LQTS type 1:LQTS type 2, hazard ratio: 9.88; p  0.03; LQTS type
3:LQTS type 2, hazard ratio: 8.04; p  0.07), whereas clinical factors, including sex and QTc duration, were asso-
ciated with a significant increase in the risk for ACA or SCD only in patients with prolonged QTc intervals (female
age 13 years, hazard ratio: 1.90; p  0.002; QTc duration, 8% risk increase per 10-ms increment; p  0.002).
Conclusions Genotype-confirmed patients with concealed LQTS make up about 25% of the at-risk LQTS population. Genetic
data, including information regarding mutation characteristics and the LQTS genotype, identify increased risk for
ACA or SCD in this overall lower risk LQTS subgroup. (J Am Coll Cardiol 2011;57:51–9) © 2011 by the
American College of Cardiology Foundation
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Phenotype-Negative Long-QT Syndrome December 28, 2010/January 4, 2011:51–9Congenital long-QT syndrome
(LQTS) is an inherited chan-
nelopathy characterized by a pro-
longed corrected QT interval
(QTc) at rest that is associated
with an increased predisposition
for polymorphic ventricular ar-
rhythmias and sudden cardiac
death (SCD) in young subjects
without structural heart disease
(1). To date, more than 500 mu-
tations have been identified in 12
LQTS-susceptibility genes, with
the long-QT syndrome type 1
(LQT1), long-QT syndrome
type 2 (LQT2), and long-QT
syndrome type 3 (LQT3) geno-
types constituting more than
5% of genotype-positive LQTS and approximately 75% of
ll LQTS (2). Risk assessment in affected patients with
QTS relies primarily on a constellation of electrocardio-
raphic (ECG) and clinical factors, including QTc interval
nd age-sex interactions (3–6). In addition, there is increas-
ng evidence that genetic information and the molecular and
ellular properties of the LQTS-causative mutation may
dentify subjects with increased risk for cardiac events
7–10). Despite these recent advances, however, currently
here are limited data regarding the clinical course and risk
actors for life-threatening events in patients with LQTS
ith normal resting QTc values, so-called silent mutation
arriers, concealed LQTS, or normal–QT interval LQTS.
See page 60
In the present study we used combined data from 7
ational LQTS registries to: 1) compare the clinical courses
f patients with LQTS and normal-range QTc intervals to
hose of patients with prolonged QTc intervals and of
enotype-negative unaffected family members; and 2) iden-
ify specific clinical and genetic risk factors for life-
hreatening cardiac events in patients with LQTS with
ormal-range QTc intervals.
ethods
tudy population. The study population comprised 3,386
enotyped subjects drawn from the Rochester, New York,
nrolling center (center 1) of the International LQTS
egistry (n 2,630), the Netherlands LQTS Registry (n
91), and the Japanese LQTS Registry (n 205), as well as
rom data submitted by other investigators specifically for
his collaborative mutation analysis project from Denmark
n  90), Italy (n  28), Israel (n  25), and Sweden (n 
7). Patients were derived from 552 proband-identified
CNQ1 (LQT1), KCNH2 (LQT2), and SCN5A (LQT3)
Abbreviations
and Acronyms
ACA  aborted cardiac
arrest
ECG  electrocardiographic
LQTS  long-QT syndrome
LQT1  long-QT syndrome
type 1
LQT2  long-QT syndrome
type 2
LQT3  long-QT syndrome
type 3
QTc  corrected QT
interval
SCD  sudden cardiac
deathamilies. The proband in each family had otherwise unex- plained, diagnostic QTc prolongation or experienced
QTS-related symptoms. Patients were excluded from the
tudy if they had: 1) 1 LQTS identified mutation (n 
0); 2) Jervell and Lange-Nielsen syndrome with deafness
nd 2 KCNQ1 mutations or 1 known KCNQ1 mutation and
ongenital deafness (n  2); and 3) no identified mutation
n genetic testing with prolonged QTc interval (440 ms
n  428]).
ata collection and end point. Routine clinical and rest
CG parameters were acquired at the time of enrollment in
ach of the registries. Measured parameters on the first
ecorded electrocardiogram included QT and R-R intervals
n milliseconds, with QT interval corrected for heart rate
sing Bazett’s (11) formula. Clinical data were collected on
rospectively designed forms with information on demo-
raphic characteristics, personal and family medical histo-
ies, ECG findings, therapies, and events during long-term
ollow-up. Data common to all LQTS registries involving
enetically tested subjects were electronically merged into a
ommon database for the present study. In addition, infor-
ation regarding QT interval–prolonging medications and
riggers for cardiac events was collected through a specific
uestionnaire for patients enrolled the U.S. portion of the
egistry.
The primary end point of the study was the occurrence of
first life-threatening cardiac event, comprising aborted
ardiac arrest (ACA; requiring external defibrillation as part
f the resuscitation or internal defibrillation in patients with
mplantable cardioverter-defibrillators) or LQTS-related
CD (abrupt in onset without evident cause, if witnessed, or
eath that was not explained by any other cause if it
ccurred in a nonwitnessed setting such as sleep). In the
ultivariate models, follow-up was censored at age 41 years
o avoid the influence of coronary disease on the occurrence
f cardiac events. We also evaluated a secondary end point
hat included the occurrence of a first cardiac event of any
ype during follow-up (comprising syncope [defined as
ransient loss of consciousness that was abrupt in onset and
ffset], ACA, or SCD).
henotype characterization. For the purpose of this study,
he QTc interval was categorized as normal range (440
s) or prolonged (440 ms) according to accepted criteria
or the phenotypic definition of LQTS (12). Using this
efinition, the study population were categorized into 3
enotype and QTc subgroups: 1) LQTS with normal-range
Tc interval (n  469), comprising patients identified to
ave LQT1 to LQT3 mutations with QTc intervals 440
s; 2) LQTS with prolonged QTc interval (n  1,392),
omprising patients with LQT1 to LQT3 mutations with
Tc intervals 440 ms; and 3) unaffected family members
n  1,525), comprising registry subjects from genotype-
ositive proband-identified families who were genetically
ested and found to be negative for the LQTS-associated
utation, with QTc intervals440 ms (i.e., genetically andhenotypically unaffected family members).
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December 28, 2010/January 4, 2011:51–9 Phenotype-Negative Long-QT Syndromeenotype characterization. The KCNQ1, KCNH2, and
CN5Amutations were identified with the use of standard genetic
ests performed in academic molecular genetics laboratories, in-
luding the Functional Genomics Center, University of Rochester
edical Center, Rochester, New York; Baylor College of Med-
cine, Houston, Texas; Windland Smith Rice Sudden Death
enomics Laboratory, Mayo Clinic, Rochester, Minnesota; Bos-
on Children’s Hospital, Boston, Massachusetts; the Laboratory
f Molecular Genetics, National Cardiovascular Center, Suita,
apan; the Department of Clinical Genetics, Academic Medical
enter, Amsterdam, the Netherlands; and the Molecular Cardi-
logy Laboratory, Policlinico S. Matteo and University of Pavia,
avia, Italy.
Genetic alterations of the amino acid sequence were
haracterized by location and by the type of the specific
utation. The transmembrane region of each of the 3
QTS channels was defined as: 1) amino acid residues from
20 through 355 in the KCNQ1-encoded Kv7.1 channel
S1 to S6 region); 2) amino acid residues from 398 through
57 (S1 to S6 region) in the KCNH2-encoded Kv11.1
hannel; and 3) amino acid residues 129 through 417, 713
hrough 940, 1201 through 1470, and 1523 through 1740 in
he SCN5A-encoded Nav1.5 channel (13). On the basis of
rior studies that demonstrated the functional and clinical
mportance of missense mutations that are located in the
ransmembrane region of these LQTS-associated channels
9,10), mutation categories were pre-specified in the pri-
ary analysis as transmembrane-missense (mutations of the
issense type in any of the 3 transmembrane regions
escribed previously) versus nontransmembrane or nonmis-
ense (i.e., any other identified LQT1 to LQT3 mutation
hat was not transmembrane-missense).
tatistical analysis. The clinical characteristics of study
atients were compared by genotype and QTc categories
sing chi-square tests for categorical variables and t tests and
ann-Whitney-Wilcoxon tests for continuous variables.
he Kaplan-Meier estimator was used to assess the time to
first life-threatening event and the cumulative event rates
y risk groups and risk factors, and groups were compared
sing the log-rank test.
Cox proportional hazards regression analysis was carried
ut in the total study population and separately in the subset
f patients with genotype-positive LQTS. Pre-specified
ovariates in the total population model included the 3
enotype and QTc categories, sex, and time-dependent
eta-blocker therapy. The models comprising genotype-
ositive patients included the following pre-specified covari-
tes: QTc category (normal range [440 ms] vs. prolonged
440 ms]), the LQT1 to LQT3 genotypes, mutation
ocation and type, sex, QTc duration (assessed both as a
ontinuous measure [per 10-ms increase] and as a categor-
cal covariate [dichotomized at the median value of each
Tc category and assessed in separate models]), time-
ependent beta-blocker therapy, and a family history of
CD in a first-degree relative. The effect of each covariate
n outcome in each QTc category (i.e., in patients withQTS with normal-range and prolonged QTc intervals)
as assessed using interaction-term analysis, with interac-
ions tested 1 at a time. Estimates of predictor hazard ratios
n the separate normal and prolonged QTc categories were
btained using these interactions. To avoid violation of the
roportional hazards assumption due to sex-risk crossover
uring adolescence, we used an age-sex interaction term in
he multivariate models.
Because almost all the subjects were first-degree and
econd-degree relatives of probands, the effect of lack of
ndependence between subjects was evaluated in the Cox
odel with grouped jackknife estimates for family member-
hip (14). All grouped jackknife standard errors for the
ovariate risk factors fell within 3% of those obtained from
he unadjusted Cox model, and therefore only the Cox
odel findings are reported. The statistical software used
or the analyses was SAS version 9.20 (SAS Institute Inc.,
ary, North Carolina). A 2-sided significance level of 0.05
as used for hypothesis testing.
esults
he spectrum and number of LQT1-associated, LQT2-
ssociated, and LQT3-associated mutations by the pre-
pecified location and type categories are presented in
nline Table 1. Totals of 100, 177, and 41 different
utations were identified in the KCNQ1-encoded Kv7.1,
CNH2-encoded Kv11.1, and SCN5A-encoded Nav1.5 ion
hannels, respectively. Study patients with identified LQTS
utations exhibited a very wide QTc interval distribution
Fig. 1), ranging from a minimum of 350 ms to a maximum
f 800 ms (mean 450 56 ms; median 440 ms; interquartile
ange: 410 to 480 ms). QTc distribution was similar among
he 3 LQTS genotypes. Four hundred sixty-nine LQTS
utation–positive patients exhibited normal-range QTc
ntervals, constituting 25% of identified cases.
Figure 1 Distribution of QTc Interval Duration
in Genotype-Positive Patients With LQTS
Distribution of corrected QT (QTc) interval durations
in genotype-positive study patients. LQTS  long-QT syndrome.
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Phenotype-Negative Long-QT Syndrome December 28, 2010/January 4, 2011:51–9The clinical characteristics of the total study population by
enotype and QTc subgroup are shown in Table 1. The
requency of probands (defined in the registry as the first
erson in a family, living or deceased, identified to have LQTS
y the enrollment center) was highest in patients with pro-
onged QTc intervals, whereas most patients with normal-
ange QTc intervals (92%) were asymptomatic at the time of
enetic testing. The frequency of female subjects was similar
etween the unaffected subjects and patients with LQTS with
ormal-range QTc intervals and higher in patients with
rolonged QTc intervals. In mutation carriers, the frequency of
he 3 main LQTS genotypes was similar between patients with
nd without prolonged QTc intervals. However, patients with
QT1 and LQT2 with prolonged QTc intervals had a higher
requency of transmembrane-missense mutations compared
ith the corresponding genotype carriers who had normal-
ange QTc intervals. LQTS-related therapies were adminis-
Baseline and Follow-Up Characteristics ofthe Study Population by Genotype-Phen typeTable 1 Basel ne and Follow-Up Charact risthe Study Population by Genotype-P
Characteristic
Unaffected
Family Members
(n  1,525)
With N
Female 52%
Family history of SCD 8%
QTc interval (ms)
Mean  SD 412 22
Median (IQR) 420 (400–430)
Proband 8%
RR interval (ms)
Mean SD 793 221
Median (IQR) 800 (640–930)
Genotype
LQT1 NA
LQT2 NA
LQT3 NA
Mutation: TM-MS
Overall NA
LQT1 NA
LQT2 NA
LQT3 NA
Therapies
Beta-blockers 6.2%
Pacemaker 0.3%
LCSD 0.1%
ICD 0.6%
Events
Syncope 10%
ACA 0.2%
SCD 0.1%
ACA/SCD‡§ 0.3%
*p  0.05 for the comparison among the 3 genotyped categories. †
intervals 440 ms and genotype-positive patients with QTc inter
genotype-positive patients with QTc intervals 440 ms and 1.4% of AC
event for each patient was considered.
ACA  aborted cardiac arrest; ICD  implantable cardioverter-d
denervation; LQT1  long-QT syndrome type 1; LQT1  long-QT synd
MS  missense; NA  not applicable; QTc  corrected QT; SCD  suered to a significantly higher frequency of patients with (rolonged QTc intervals than to subjects in the other 2
ubgroups (Table 1).
linical course by genotype and QTc subgroup. Kaplan-
eier survival analysis (Fig. 2) demonstrated a relatively
ow rate of ACA or SCD in patients with LQTS with
ormal-range QTc intervals (4% at age 40 years and 10% at
ge 70 years). Event rates were significantly higher in
atients with prolonged QTc intervals (15% and 24% at age
0 years; log-rank p  0.001 for the comparison with the
ormal-range QTc subgroup) and significantly lower in
naffected family members (0.4% and 1% at age 70 years;
og-rank p  0.001 for the comparison with the normal-
ange QTc subgroup and for the overall difference among
he 3 subgroups). Notably, life-threatening events in pa-
ients with normal-range QTc intervals occurred mostly
fter age 10 years, whereas patients with prolonged QTc
ntervals exhibited an earlier onset of life-threatening events
f
type
ts With LQTS
Range QTc Intervals
 469)
Patients With LQTS
With Prolonged QTc Intervals
(n  1,392)
48% 61%*†
12% 19%*†
9 20 501 48
(410–440) 490 (470–520)
8% 29%*†
8 236 848 214*†
(740–1,040) 840 (700–1,000)*†
40% 39%
45% 47%
16% 14%
35% 43%
45% 61%
16% 29%†
64% 31%†
38% 54%*†
0.6% 5%*†
0.2% 1.4%*†
6% 14%*†
21% 40%*†
1.3% 8.4%*†
1.5% 4.4%*†
2.8% 11.3%*
05 for the comparison between genotype-positive patients with QTc
40 ms. ‡Appropriate ICD shocks constituted 0.04% of ACAs in
enotype-positive patients with QTc intervals 440 ms. §Only the first
tor; IQR  interquartile range; LCSD  left cardiac sympathetic
pe 2; LQT3  long-QT syndrome type 3; LQTS  long-QT syndrome;
rdiac death; TM  transmembrane.tics o
heno
Patien
ormal-
(n
41
420
88
900
p  0.
vals 4
As in g
efibrillaFig. 2).
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December 28, 2010/January 4, 2011:51–9 Phenotype-Negative Long-QT SyndromeAfter multivariate adjustment for sex, time-dependent
eta-blocker therapy, and a family history of SCD in a
rst-degree relative, patients with LQTS with normal-
ange QTc intervals were shown to have a significant 72%
p  0.001) lower risk for ACA or SCD compared with
atients with prolonged QTc intervals but also exhibited a
10-fold increase in the risk for life-threatening events
ompared with unaffected family members (Table 2). His-
ories of syncope were present in 62% of patients with
QTS with normal-range QTc intervals who had life-
hreatening events during follow-up. Accordingly, when the
omposite secondary end point of a first cardiac event of any
ype was assessed (comprising mainly non-life-threatening
yncopal episodes), patients with normal-range QTc inter-
als were consistently shown to be at a lower risk compared
ith those with prolonged QTc intervals (hazard ratio
HR]: 0.47; 95% confidence interval [CI]: 0.33 to 0.59; p
.001) and at a higher risk compared with unaffected family
embers (HR: 5.20; 95% CI: 4.19 to 6.44; p  0.001).
isk factors for ACA or SCD in patients with LQTS
ith and without prolonged QTc intervals. Interaction-
erm analysis demonstrated significant differences in risk
actors for life-threatening events between the 2 LQTS
ubgroups (Table 3). In patients with normal-range QTc
ntervals, the LQT1 and LQT3 genotypes were associated
ith respective 10- and 8-fold increases in the risk for
ife-threatening events compared with the LQT2 genotype.
n contrast, in patients with prolonged QTc intervals, the
Figure 2 Rate of ACA or SCD by Genotype and QTc Category
Kaplan-Meier cumulative probabilities of aborted cardiac arrest (ACA) and sud-
den cardiac death (SCD) by genotype and corrected QT (QTc) subgroup.
LQTS  long-QT syndrome.
Multivariate Analysis: Risk for ACA or SCDAmong the 3 Genotype and QTc ategories*Table 2 Multivariate Analysis: Risk for ACAAmong the 3 Genotype and QTc Ca
Genotype and QTc Subgroup
LQTS with prolonged QTc interval vs. unaffected family mem
LQTS with normal-range QTc interval vs. unaffected family m
LQTS with normal-range QTc interval vs. LQTS with prolonge*Model also adjusted for sex (female age 13 years) and time-dependent be
CI  confidence interval; HR  hazard ratio; other abbreviations as in TablQT1 genotype was associated with one-half the risk of the
QT2 genotype (p  0.002), with a statistically significant
enotype– by–QTc subgroup interaction (p  0.006)
Table 3, first row), and the LQT3 genotype showed a
imilar risk to the LQT2 genotype, without a statistically
ignificant genotype–by–QTc subgroup interaction (Table 3,
econd row).
The location and type of the LQTS mutation were
hown to be significant risk factors for ACA or SCD in
atients with normal-range QTc intervals. In this LQTS
ubset, transmembrane-missense mutations were associated
ith a pronounced 6-fold (p  0.006) increase in the risk
or ACA or SCD compared with nontransmembrane or
onmissense mutations. In contrast, in patients with pro-
onged QTc intervals, transmembrane-missense mutations
ere not independently associated with outcomes (Table 3,
hird row). Notably, when the secondary end point of
ardiac events of any type was assessed, transmembrane-
issense mutations were shown to be an independent risk
actor in both LQTS subgroups (normal-range QTc inter-
al, HR: 1.71; 95% CI: 1.16 to 2.34; prolonged QTc
nterval, HR: 1.39; 95% CI: 1.17 to 1.65).
Consistent results demonstrating an association between
ransmembrane-missense mutations and the risk for ACA
r SCD in patients with normal-range QTc intervals were
hown when the reference group (comprising nontrans-
embrane or nonmissense mutations) was further divided
nto 3 subcategories, including nonmissense mutations in
he transmembrane region, missense mutations in the non-
ransmembrane region, and nonmissense mutations in the
ontransmembrane region (HR 4.0 for all 3 compari-
ons). Accordingly, patients with normal-range QTc inter-
als with transmembrane-missense mutations experienced a
elatively high rate of ACA or SCD during follow-up (9%
t age 40 years and 21% at age 70 years), whereas patients
ith normal-range QTc intervals with other mutations had
very low event rate (1% at age 40 years and 5% at age 70
ears; log-rank p for overall difference  0.005) (Fig. 3A).
n contrast, in patients with prolonged QTc intervals, there
as no statistically significant difference in the rate of ACA
r SCD between the 2 mutation categories (16% and 14% at
0 years, respectively, p  0.18) (Fig. 3B).
Clinical and ECG factors, including sex and QTc dura-
ion, were shown to be associated with a significant increase
n the risk for ACA or SCD only in patients with prolonged
Tc intervals (Table 3, rows 4 to 6). In contrast, in patients
D
ies*
HR 95% CI p Value
36.53 13.35–99.95 0.001
rs 10.25 3.34–31.46 0.001
interval 0.28 0.16–0.49 0.001or SC
tegor
bers
embe
d QTcta-blocker therapy.
e 1.
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Phenotype-Negative Long-QT Syndrome December 28, 2010/January 4, 2011:51–9ith normal-range QTc intervals, sex was not a significant
isk factor, and QTc duration was not independently asso-
iated with a significant increase in the risk for ACA or
CD when assessed as a continuous measure or when
ichotomized at the median value (420 ms).
As suggested previously (15), the presence of a family
istory of SCD in any first-degree relative was not shown to
e an independent predictor of ACA or SCD in patients
ith either normal-range QTc intervals (HR: 0.89; 95% CI:
.63 to 1.25; p  0.50) or prolonged QTc intervals (HR:
.40; 95% CI: 0.32 to 6.17; p  0.65) after adjustment for
enetic and clinical factors.
Beta-blocker therapy was administered to 38% of patients
ho had normal-range QTc intervals compared with 54% of
he patients who had prolonged QTc intervals (p  0.001)
Table 1). Treatment with beta-blockers was associated with
n overall significant 25% reduction in the risk for ACA or
CD in the total study population (95% CI: 0.70 to 0.80; p
.001), with similar effects in patients with normal-range QTc
ntervals and those with prolonged QTc intervals (p for
eta-blocker–by–LQTS subset interaction  0.45).
haracteristics of fatal or near-fatal cases with a normal-
ange QTc intervals. The characteristics of patients with
ormal-range QTc intervals who experienced ACA or SCD
uring follow-up are shown in Table 4. The mean age at
ccurrence of the lethal or near-lethal event in this popu-
ation was 25.9  4.5 years. Nine of the patients (53%) who
xperienced events were women, and 4 (24%) were treated
ith beta-blockers are the time of the events. In patients
ith normal-range QTc intervals with available data regard-
ng therapies and triggers at the time of the events, none
ere reported as being treated with a QT interval–
rolonging drugs at the time of ACA or SCD, and the
ajority of the lethal or near-lethal events were not associ-
gory*Interval Category*
val LQTS and Prolonged QTc Interval
lue HR (95% CI) p Value p Value for Interaction
0.53 (0.35–0.79) 0.002 0.006
1.07 (0.70–1.63) 0.77 0.08
6 1.24 (0.88–1.76) 0.22 0.02
1.90 (1.26–2.86) 0.002 0.53
1.08 (1.05–1.10) 0.001 0.58
2.96 (2.06–4.26) 0.001 NA
enotype-positive LQTS (n  1,861). Covariates in the models included QTc category (440 ms vs.
er 10-ms increase]), time-dependent beta-blocker therapy, and a family history of SCD; the effect
ervals was assessed by interaction-term analysis, with interactions tested 1 at a time. Estimates
ing these interactions. Virtually identical results for all pre-specified risk factors were also obtained
s were obtained from separate models that assessed the risk associated with QTc values greater
prolonged QTc intervals (median 500 ms).Figure 3
Rate of ACA or SCD in Patients
With Normal-Range and Prolonged QTc
Intervals by Mutation Location and Type
Kaplan-Meier cumulative probabilities of aborted cardiac arrest (ACA) and sud-
den cardiac death (SCD) by mutation location and type in patients with long-QT
syndrome (LQTS) with (A) corrected QT (QTc) intervals 440 ms and (B) QTc
intervals 440 ms.isk Factors for ACA or SCD in Patients With LQTS by QTc Interval CateTable 3 Risk Factors for ACA or SCD in Patients With LQTS by QTc
LQTS and Normal-Range QTc Inter
Variable HR (95% CI) p Va
Genotype
LQT1 vs. LQT2 9.88 (1.26–37.63) 0.03
LQT3 vs. LQT2 8.04 (0.85–36.03) 0.07
Mutation location and type
TM-MS vs. non-TM-MS 6.32 (1.71–23.33) 0.00
Sex
Female age 13 yrs vs. male age 13 yrs 1.32 (0.42–4.17) 0.64
QTc interval (ms)
Per 10-ms increase 1.20 (0.81–1.78) 0.35
Median vs. median† 1.03 (0.36–2.98) 0.95
Cox proportional hazards regression modeling was carried out in models that included all patients with g
440 ms), genotype, mutation location and type, sex, QTc interval (assessed as a continuous measure [p
f each covariate in patients with normal-range (440 ms) and those with prolonged (440 ms) QTc int
f predictor hazard ratios in the separate normal-range and prolonged QTc interval groups were obtained us
rom the models that did not include appropriate ICD shocks as part of the composite end point. †Result
han or equal to the median in patients with LQTS with normal-range QTc intervals (median 420 ms) andted with exercise or arousal triggers (Table 4).
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n this study, we assessed the clinical courses and risk factors
or life-threatening events in LQTS patients with genetically-
onfirmed LQTS who do not exhibit the disease’s phenotypic
allmark of QT interval prolongation, otherwise referred to as
oncealed LQTS, normal–QT interval LQTS, or genotype-
ositive/ECG phenotype–negative LQTS. Similar to prior
tudies (16), we have shown that patients with LQT1 to
QT3 exhibit a wide QTc distribution, with approximately
5% having QTc intervals well within the normal range. The
ate of ACA or SCD in patients with LQTS with normal-
ange QTc intervals was shown to be very low (4% from birth
hrough age 40 years, corresponding to an approximate event
ate of 0.13% per year). Comparatively, however, this very low
isk subset of the LQTS population still exhibited a 10-fold
ncrease in the risk for life-threatening events compared with
enetically and phenotypically unaffected family members.
mportantly, predictors of life-threatening events were shown
o be significantly different between LQTS patients with and
ithout prolonged QTc intervals. In the latter LQTS sub-
roup, genetic data, including knowledge of genotype and
utation characteristics, were shown to identify the risk for
CA or SCD, whereas in the former LQTS subgroup, female
ex in the post-adolescence period and QTc duration were
dentified as the predominant risk factors for life-threatening
vents.
The clinical courses of patients with LQTS are variable
ecause of incomplete penetrance (17). They are influenced by
ge, genotype, sex, environmental factors, therapy, and possibly
ther modifier genes (1–10). Recent studies from the Interna-
ional LQTS Registry that assessed the risk for life-threatening
haracteristics of ACA and SCD Cases With Normal-Range QTc IntTable 4 Characteristics of ACA and SCD Cases With Normal-Ra
Case Event
Event Age
(yrs) Female
QTc Interval
(ms) BB† LC
1 SCD 0.5  390 
2 ACA 10 430 
3 ACA/shock 11  400 
4 SCD 13  440 
5 ACA 14  410 
6 SCD 16  420 
7 ACA 16  440 
8 SCD 18  430 
9 ACA 18  410 
10 SCD 21  380 
11 SCD 22  440 
12 SCD 28  410 
13 ACA 35  420 
14 ACA 46  440 
15 SCD 48  430 
16 ACA 54  420 
17 SCD 69  380 
Data regarding triggers for cardiac events and treatment with QT interval–prolonging medications
At time of event. ‡Implanted or performed before event.
BB  beta-blocker therapy; E/A  exercise/arousal trigger for event; NA  not available; PM vents in patients with LQTS have consistently demonstrated ehat ECG and clinical risk factors, including the QTc interval
nd age-sex interactions, identify increased risk in the LQTS
opulation (3–5). These studies, however, included mainly
henotype-positive patients with LQTS with QTc intervals
50 ms. Thus, the effect of genetic data on outcomes in these
tudies was not statistically significant after adjustment for the
CG and clinical factors. The present study population,
omprising 1,861 genetically confirmed patients with the
QT1 to LQT3 genotypes, extends the data derived from
rior studies and demonstrates that risk factors for life-
hreatening events are significantly different between patients
ith LQTS with and without QTc prolongation. Consistent
ith prior studies, we have shown that in patients with LQTS
ho exhibit prolonged QTc durations, ECG information and
linical factors can be used to identify the risk for life-
hreatening events. In contrast, in mutation-positive subjects
ith normal-range QTc intervals, genetic factors, including
nowledge of the LQTS genotypes and the mutation location
nd type, identified patients who were at an increased risk for
CA or SCD after adjustment for ECG and clinical data.
Sex was not a significant risk factor for cardiac events
n patients with normal-range QTc intervals. Further-
ore, patients with normal-range QTc intervals dis-
layed a similar frequency of women as unaffected family
embers, whereas the frequency of women was signifi-
antly higher among patients with prolonged QTc inter-
als. These findings are in accordance with earlier evi-
ence of longer QTc intervals in LQTS women than in
en (18), resulting in a marked female predominance in
henotypically affected patients (3–5). The biologic basis
or this sex difference might be the down-regulation of
sQTc Intervals
PM‡ ICD‡ QT PD Trigger* Genotype
Mutation Location
and Type
   NA LQT3 Non-TM-MS
   Exercise LQT1 TM-MS
   Non-E/A LQT1 TM-MS
  NA NA LQT1 TM-MS
   Exercise LQT1 Non-TM-MS
   Non-E/A LQT3 TM-MS
   Arousal LQT1 TM-MS
   Non-E/A LQT1 TM-MS
   Exercise LQT1 TM-MS
   Arousal LQT2 Non-TM-MS
  NA NA LQT1 TM-MS
   Exercise LQT1 TM-MS
   Non-E/A LQT3 TM-MS
  NA NA LQT2 TM-MS
   Non-E/A LQT2 Non-TM-MS
   Non-E/A LQT3 Non-TM-MS
  NA NA LQT1 TM-MS
vailable for study patients who were enrolled in the U.S. portion of the International LQTS Registry.
aker; QT PD  QT interval–prolonging drug; other abbreviations as in Tables 1 and 2.ervalnge
SD‡

















were axpression of cardiac potassium-channel genes by female
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Phenotype-Negative Long-QT Syndrome December 28, 2010/January 4, 2011:51–9ex hormones, which have been shown to prolong the QT
nterval in both congenital and drug-induced LQTS
19,20). These hormonal effects may explain the present
ndings of a lower frequency of LQTS women with
ormal-range QTc intervals.
Recent genotype-phenotype studies have shown that mis-
ense mutations located in the transmembrane region, which is
esponsible for forming the ion conduction pathway of the
hannel, are associated with a significantly higher risk for
ardiac events compared with mutations that are located in
ther regions of the LQTS channel (9,10). The present study
lso shows that transmembrane-missense mutations are asso-
iated with a significantly higher risk for cardiac events of any
ype (predominated by syncopal episodes) in patients with
QTS with both normal-range and prolonged QTc intervals.
owever, our findings suggest that data regarding mutation
haracteristics are important for the assessment of life-
hreatening events (comprising ACA and SCD) mainly in
atients with normal-range QTc intervals, in whom informa-
ion derived from ECG and clinical data is more limited. In
his LQTS subset, missense mutations located in the trans-
embrane region were shown to be associated with a6-fold
ncrease in the risk for life-threatening events and with a
linically meaningful rate of ACA or SCD (9%) from birth
hrough age 40 years.
The mechanisms relating to the occurrence of life-
hreatening ventricular tachyarrhythmias in phenotype-
egative patients with LQTS are not clear. In the present
tudy, none of the patients with normal-range QTc intervals
ho experienced ACA or SCD took QT interval–prolonging
edications at the time of the events. Furthermore, most
vents in patients with normal-range QTc intervals were not
elated to exercise or arousal triggers (Table 4). An ECG
racing from a patient with the LQT1 genotype who devel-
ped arrhythmic events despite a normal-range QTc interval
howed spontaneous generation of polymorphic ventricular
achycardia without preceding extrasystolic pauses or sudden
inus rate acceleration (Fig. 4), possibly explaining the occur-
ence of ACA or SCD in study patients with normal-range
Tc intervals who were treated with beta-blockers at the time
f the events.
tudy limitations. Most study patients did not undergo
omprehensive genetic testing for all currently known mu-
ations that may predispose to arrhythmic risk. Thus, it is
ossible that the coexistence of modifier genes affected the
utcomes of patients with LQTS with normal-range QTc
ntervals who experienced life-threatening cardiac events. In
ddition, to provide an estimation of event rates among
naffected family members, we included in the control
roup subjects who were both genotype negative and also
ad normal-range QTc intervals (and excluded genotype-
egative subjects with prolonged QTc intervals due to
ossible unidentified mutations in this subset). Therefore,
he overall frequency of genotype-positive subjects in the
otal population may not represent the true penetrance of
QTS in affected families.Figure 4 Polymorphic Ventricular Tachycardia
in a Patient With a Normal-Range QTc Interval
Spontaneous generation of polymorphic ventricular tachycardia in a patient with
long-QT syndrome type 1 with a normal-range corrected QT (QTc) interval.
(A) The patient had a QTc duration of 410 ms on baseline electrocardiography.
(B) Electrocardiographic tracing at the time of arrhythmic event demonstrates
sinus rate with an RR interval of 1,000 ms without significant QT prolongation
before the arrhythmia. (C) The patient was treated with nadolol and received
an implantable cardioverter-defibrillator but continued to exhibit arrhythmic epi-
sodes that were recorded on implantable cardioverter-defibrillator interrogation.
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December 28, 2010/January 4, 2011:51–9 Phenotype-Negative Long-QT SyndromeThe threshold value of 440 ms for the definition of a
ormal-range QTc in the present study was based on the
iagnostic criteria for LQTS proposed by Schwartz et al.
12), which define a prolonged QTc interval as 450 ms in
ale patients and 460 ms in female patients. We chose to
se a uniform approach by selecting 440 ms as the upper
imit of normal rather than having separate phenotypic
efinitions for male and female patients. It should also be
oted that 2.5% of infants and 10% to 20% of adults exceed
his cutoff (21). Thus, the 440-ms value is not meant to
uggest an LQTS diagnosis on its own.
onclusions
he present study shows that patients with LQTS who
xhibit normal-range QTc intervals constitute approxi-
ately 25% of the LQTS population and have a signifi-
antly lower risk for life-threatening events compared with
henotypically affected patients but also exhibit a significant
ncrease in the risk of ACA or SCD compared with
naffected family members. Missense mutations in the
ransmembrane regions of the ion channels, mainly in
atients with LQT1 and LQT3, were shown to identify
atients with normal-range QTc intervals who have an
ncreased risk for ACA or SCD. In contrast, increments in
Tc duration were not shown to be significantly associated
ith increased risk for life-threatening events in this pop-
lation. These findings suggest that: 1) risk assessment in
henotype-negative family members of LQTS probands
hould include genetic testing, because a positive genetic
est result in a family member with a normal-range QTc
nterval implies an overall 10-fold increase in the risk for
CA or SCD compared with a negative test result in an
naffected family member; 2) genetic data may be used to
dentify phenotype-negative patients with LQTS who are at
ncreased risk for fatal ventricular tachyarrhythmias inde-
endently of QTc duration; and 3) LQTS mutation–
ositive patients with normal-range QTc intervals who are
dentified as having increased risk for life-threatening events
n the basis of genotype and mutation characteristics (i.e.,
QT1 and LQT3 with transmembrane-missense muta-
ions) should be carefully followed and receive a similar
anagement strategy as phenotype-positive patients with
QTS, including avoidance of QT-prolonging medications
22), routine therapy with beta-blockers, and possibly im-
lantable cardioverter-defibrillator therapy in those who
emain symptomatic despite medical therapy. Conversely,
atients with the lowest risk profile of already low risk,
oncealed LQTS (i.e., concealed LQT2 and non-
ransmembrane-missense LQT1 and LQT3) may represent
he nominally near zero risk subpopulation(s) of LQTS in
eed of only preventative health recommendations such as
T drug avoidance. aeprint requests and correspondence: Dr. Ilan Goldenberg,
eart Research Follow-Up Program, Box 653, University of
ochester Medical Center, Rochester, New York 14642. E-mail:
lan.goldenberg@heart.rochester.edu.
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APPENDIX
or a table about KCNQ1, KCNH2, and SCN5A mutations by amino acid
oding, frequency, location, and type, please see the online version of this
rticle.
